Aslı Geçgel

FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

Background: The optimal use of chemotherapy rechallenge in later-line metastatic colorectal cancer (mCRC) remains uncertain. We compared third-line FOLFOX plus bevacizumab rechallenge with regorafenib and examined whether the oxaliplatin-free interval was associated with treatmen...